NGAL is a potential new biomarker for the acute kidney injury (AKI).

Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury and peaks within a very short time – as much as 24 hours or more before any significant rise in serum creatinine. The finding of a raised urinary or plasma level of NGAL cannot be independently diagnostic of any single pathology, since a variety of independent pathologies (e.g. inflammation, infection and certain types of cancer) are associated with raised levels of urinary or plasma NGAL.

Kit features

• Simple ELISA format - easy to perform
  
  • Ready-to-use calibrators and working solutions
  • Pre-coated ELISA strips
  • All incubations performed at room temperature
• Easy storage
  
  • All components are stored at 4°C
• Automation possible on open ELISA workstations